Pharmacological Properties of Trichostatin A, Focusing on the Anticancer Potential: A Comprehensive Review.

The antioxidant activity of TSA was reported in several studies using several in vitro models [ 11 , 12 , 13 , 14 ] ( Table 1 ). Yang et al. [ 14 ] evaluated the antioxidant activity of TSA against TGF- β -induced ROS accumulation in telomerase-immortalized human corneal fibroblasts. These authors found that TSA exhibits antioxidant activity manifested by the reduction in MDA levels, the elevation of intracellular glutathione (GSH) level and cellular total antioxidant capacity, and the decrease in cellular ROS and H 2 O 2 accumulation. This compound also induced Nrf 2 nuclear translocation and the upregulation of the expression of Nrf 2 -ARE downstream antioxidant genes. Using immunoblot analysis and the (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, Jeong and colleagues examined the antioxidant potential of TSA in human bone marrow-mesenchymal stem cells (hBM-MSCs) after exposure to hydrogen peroxide (H 2 O 2 ) [ 12 ]. These researchers showed that TSA suppresses oxidative stress by various mechanisms such as the reduction of intracellular ROS and the increase in the expression of phosphorylated-FOXO 1 and phosphorylated-superoxide dismutase-2 (SOD 2 ) [ 12 ] ( Figure 2 ). In another study, TSA decreased the levels of MDA and increased the expression of FoxO 3 a, SOD 2 and catalase (CAT), which may be related to the promotion of the level of H 4 acetylation of the FoxO 3 a promoter region in H 9 c 2 rat myocardial cell line injury mediated by oxidative stress [ 11 ]. Similarly, Qiu and coworkers [ 13 ] investigated the antioxidant effect of TSA against human lens epithelial cells (HLECs) following exposure to ultraviolet-B (UVB) by evaluating the levels of superoxide dismutase (SOD), ROS, MDA, and total antioxidant capacity (T-AOC). Results showed that this compound has significantly elevated the SOD and CAT levels, and reduced MDA and ROS levels, thus protecting HLECs from oxidation. Summarized in Table 1 are the antioxidant activities of trichostatin A. The antioxidant effects of TSA are mainly related to its capacity to inhibit enzymes involved in ROS generation. Moreover, the modulation of gene expression of proteins controlling ROS production has also been revealed ( Table 1 ). Other suggestions about antioxidant mechanisms of TSA related to the effect of this natural compound on a molecular system involved in oxidative stress generation such as NADPH oxidase, which is mainly implicated in some human cancers.

Diabetes is a complex multifactorial disease expressed by a disorder of glucose concentration in the blood. The anti-diabetic effect is expressed by the capacity of anti-diabetic molecules to reduce blood glucose levels, increase insulin secretion, and protect the β-pancreatic cells as well as prevent the complications of diabetes. Within this context, the anti-diabetic effect of TSA has been investigated by several [ 15 , 16 , 17 ]. Noh et al. [ 16 ] investigated the effect of TSA in streptozotocin (STZ)-induced diabetic kidneys. These authors showed that this molecule does not affect blood glucose or kidney/body weight ratio but significantly decreases the urinary excretion of proteins and creatinine. To elucidate the mechanism of an antifibrotic effect of TSA in diabetes, they carried out an in vitro study using normal rat kidney tubular epithelial (NRK52-E) cells stimulated with TGF-β1. Results revealed that the TSA prevents the increase in fibronectin, collagen I, and α-SMA and the decrease in E-cadherin expression at both mRNA and protein levels. Another study was conducted to assess the effect of this molecule on insulin secretion from β-cells, GLP-1 secretion from L-cells, and recombinant insulin secretion from engineered L-cells by exposing them to TSA for 24 h ( Figure 3 ). Results indicated that TSA treatment increased the secretion per viable cell in a dose-dependent manner for all cell types in a way that could significantly improve the regulation of blood glucose in diabetes. TSA’s effect on mRNA levels was variable, but it enhanced the intracellular polypeptide secretion [ 17 ]. Recently, An and collaborators [ 15 ] studied the capacity of TSA to ameliorate the peripheral nerve degeneration of diabetic peripheral neuropathy using cultured rat Schwann cells (RSC96) and streptozotocin (STZ) induced diabetes in rats. They found that treatment with TSA reverses the high glucose condition resulting in the downregulation of BDNF (brain-derived neurotrophic factor) expression in Schwann cells. It also promoted GRP78 expression and the binding ability of GRP78 with BDNF, which mediated TSA-improved BDNF expression in high glucose-cultured Schwann cells. TSA was also involved in UPR (unfolded protein response)-associated transcription factor XBP-1 s and ATF6. Listed in Table 2 are the antidiabetic effects of trichostatin A. According to different obtained results, TSA can be considered a potent antidiabetic drug with its other molecular actions at subcellular, cellular, and molecular levels. Indeed, with its actions on molecular targets such as the control of mRNA, TSA is among the natural antidiabetic compounds by which novel targeted therapy can be developed for diabetes mellitus.

The inhibition of inflammation is one of the most important approaches to tackling numerous complicated pathologies such as cancer and atherosclerosis. Several bioactive compounds are well-known for their anti-inflammatory effect. In this regard, numerous studies have dealt with the anti-inflammatory activity of TSA [ 18 , 19 , 20 , 21 , 22 ]. Choi et al. [ 25 ] evaluated the anti-inflammatory effect of TSA in a mouse asthma model. Results showed that TSA attenuates the development of allergic airway inflammation by decreasing the expression of CD4+ T cell infiltration cytokines such as IL-4 and IL-5, and IgE ( Figure 4 ). On the other hand, Han and Lee [ 19 ] investigated the effect of TSA on lipopolysaccharide-(LPS)-stimulated macrophages using enzyme immunoassay, Western blot analysis and RT-PCR. These researchers found that the pretreatment with TSA significantly reduces levels of mRNA and proteins and decreases the proinflammatory cytokines (TNF-α, IL-6, and IL-1β). This compound also increased the level of the immunosuppressive cytokine IL-10 and reduced the cell surface markers of macrophage maturity ( Figure 4 ). In another experimental model, TSA enhanced palmitic acid-induced IL-6 production and the expression of inflammatory genes induced by LPS in preadipocytes. It additionally enhanced the expression of inflammatory proteins and NF-κB-dependent transcriptional activity, which might be caused by the increase in the acetylation of NF-κB p65 at lysine 310 and the duration of the nuclear translocation of NF- κB [ 21 ]. Similarly, Zhang and colleagues [ 22 ] evaluated the LOX inhibitory effect of TSA in phorbol myristate acetate-induced macrophages. Results revealed that TSA exhibits potent anti-inflammatory activity by decreasing the levels of TNF- α , IFN- γ , IL-10 and IL-18 and increasing the acetylation level of NF-κB and p65. TSA inhibited inflammation by enhancing histone acetylation to selectively suppress the expression of proinflammatory genes ( Figure 4 ). Recently, TSA was evaluated in alveolar macrophages using a lipopolysaccharide (LPS)-induced inflammatory response [ 20 ]. The results revealed a potent inflammatory effect, which might be triggered by inhibition of the TNF-α molecule and the upregulation of miR-146a expression. Shown in Table 3 are the anti-inflammatory effects of TSA. According to the results of various works, it seems that TSA exerts very interesting anti-inflammatory effects with multiple mechanisms. However, the number of works remains limited using less varied experimental approaches. Furthermore, other investigations using other in vivo models could give more significant results.

TSA inhibited the growth of different cancer cells via cycle arrest and apoptosis. This compound suppressed the invasion and migration and reduced the radio resistance in many cancer cell lines in a time- and dose-dependent manner. According to the literature, numerous studies investigated the cytotoxicity impact of TSA and the mechanisms by which TSA affects cancer cells. Although the antitumor activity of TSA seems to be strongly linked to its HDAC inhibitory effect, this compound’s antitumor molecular mechanisms are multiple and target different pathways. Table 4 lists the anticancer activity of trichostatin A along with pertinent references. The mechanisms involved in anticancer effects of TSA are different and related to each type of cancer. These mechanisms are depending to molecular interaction between TSA and main targets of cancer cells. In the following sections, we describe the anticancer effects of TSA against each type of cancer and the mechanisms involved. Research findings showed that TSA inhibits differentiation and proliferation and tumor sphere formation of glioblastoma (GBM) [ 52 , 141 , 142 ]. In addition, TSA upregulated the expression of numerous tumor suppressor genes through epigenetic modification in GBM [ 143 ]. The TSA-induced cell cycle arrest in GBM was associated with the upregulation of p21 WAF1 and p53, and the downregulation of cell cycle regulators such as cdk4 and 6, and cyclin D1 with the reduction in phosphorylated Rb and Akt [ 141 , 142 , 144 , 145 ]. Sassi et al. [ 52 ] reported that TSA inhibited the proliferation and colony formation of U87 glioblastoma cells without affecting their viability and migration. Similarly, Hoering et al. [ 27 ] showed that TSA induces apoptosis of tumor cells, enhances the sensibility of GBM cells to innate immune responses in vitro and delays tumor growth of GBM xenografts in vivo . These findings prompted more investigations to involve TSA in improving brain cancer therapy. In this respect, a study on the human malignant glioma cell lines LNT- 229 and LN-308 NMRI nude mice revealed that TSA causes upregulation of natural killer group-2 member-D (NKG2D) ligands and immunogenicity in GBM cells and the retardation of tumor growth of GBM xenografts ( in vivo ) [ 27 ]. In neuroblastoma, TSA inhibited cell viability in neuroblastic-type NB cells by promoting the acetylation of Ku70, a Bax-binding protein, which resulted in Bax release and its activation, and consequently in cell death. TSA-induced cell death in neuroblastoma cells was linked with CREB-binding protein (CBP) expression, where the upregulation of CBP expression interrupted Bax–Ku70 binding in neuroblastic cell types and sensitized them to TSA. At the same time, the down-regulation of CBP enhanced their resistance to TSA [ 114 ]. TSA exhibited potent antitumor activity against human tongue squamous cell carcinoma (TSCC) in vitro by inducing cell cycle arrest and apoptosis with inhibition of cell proliferation and invasion. This effect was mediated by the downregulation of hypoxia-inducible factor-1α (HIF-1α) protein and vascular endothelial growth factor (VEGF) at the protein and mRNA levels under both normoxic and hypoxic conditions. HIF-1α is a transcription factor able to enhance tumor angiogenesis at a high level via the upregulation of VEGF [ 122 ]. TSA suppressed the expression of HIF-2α protein in fibrosarcoma cell line HT1080 via a proteasome-dependent manner [ 14 ] ( Figure 5 ). Ahn et al. [ 23 ] revealed the potential value of TSA in inhibiting oral tumor growth by investigating the mechanisms underlying the antitumor activity of TSA on human oral squamous carcinoma cells. TSA inhibited cell proliferation in YD-10B cells as revealed by the MTT assay. TSA also arrested cell cycle progression at the G2/M phase through the upregulation of p21 waf expression, downregulation of Cyclin B1, and reduction of the inhibitory phosphorylation of Cdc2 ( Figure 5 ). Additionally, TSA induced mitochondrial membrane destruction after 48 h of treatment. TSA also caused cytochrome c release which increased the proteolytic activation of caspase-3 and caspase-7 in YD-10B cells [ 23 ]. TSA significantly inhibited the proliferation of human nasopharyngeal carcinoma (NPC) cells in poorly differentiated NPC cell line CNE2 and the undifferentiated C666–1 cell. Short-term treatment with TSA inhibited PNC cells by inducing cell cycle arrest with the concomitant upregulation of CDK6 expression and the downregulation of cyclinD1 and E1, CDK2 and 4, p16 and p21 expression in both CNE2 and C666–1 cell line. The short-term TSA treatment induced EMT-like morphological changes without increasing cell invasion ability in NPC cells [ 110 ]. To the best of our knowledge, there is no investigation on the long-term effect of TSA on NPC cell invasion and migration. Thus, the study of the mechanism by which TSA can promote cancer cell invasion in nasopharyngeal carcinoma and the combination of TSA with known EMT inhibitors can help to improve the use of TSA in nasopharyngeal carcinoma therapy. In human lung adenocarcinoma, TSA inhibited cell proliferation and migration with or without TGF-β. TSA acted via the alteration of tight junction proteins that play a key role in the function of the cells. TSA induced the downregulation of claudin-2 (CLDN-2) and the upregulation of angulin-1/LSR along with the induction of cellular metabolism in A549 cells [ 111 ]. CLDN-2, upregulated in lung cancer tissues, results in the proliferation of lung cancer cells, while the downregulation of angulin-1/LSR causes malignancy. The anticancer activity of TSA against human lung cancer could be mediated by the upregulation of Krüppel-like factor 4 (klf4) which acts as a tumor-suppressor in the A549 cell line upon TSA treatment [ 140 ]. TSA also inhibited radiation-induced EMT and reduced cancer cell migration in the A549 cell line. TSA could reverse radiation-induced lung EMT via the upregulation of E-cadherin expression, which was associated with the inactivation of the signaling molecule, TGFb1, and the decline of Snail and slug transcription factors recognized as enhancers of EMT [ 95 , 146 ]. Choi et al. [ 25 ] provided important new insights into the possible molecular mechanisms of the anti-cancer activity of TSA. In a study conducted on a human lung carcinoma cell line A549, treatment with TSA caused inhibition of the viability and induction of apoptosis in a concentration-dependent manner. Apoptosis of the A549 cells was mediated by the alteration in Bcl-2 expression and the activation of caspase-3 and caspase-9 proteases. The anticancer effect of TSA was also associated with the specific inhibition of COX-2 expression and PGE production. In a study conducted on human lung carcinoma cell line A549, TSA treatment caused growth inhibition and morphological changes in a concentration-dependent manner. This effect was accompanied by a marked inhibition of cyclins, positive regulators of cell cycle progression, which was attributed to the control of the overexpression of tumor suppressor p53 and Cdk inhibitors [ 28 ]. In the ZAP-Grg1 transgenic mouse line, TSA suppressed lung adenocarcinoma development. This was attributed to the inhibition of ErbB1 and ErbB2 expression and the repression of vascular signaling through VEGF [ 83 ]. Kim et al. [ 78 ] examined the effects of TSA on osteoclast differentiation induced by the differentiation factor RANKL. These researchers showed that inhibition of HDAC by TSA suppressed osteoclastogenesis in vitro and in vivo . These results implicated c-Fos as an interesting potential target of TSA function and suggested that the in vivo TSA can diminish inflammatory bone destruction. In another study, stopping of cell growth and inhibition of colony formation in lung cancer cells were attributed to the increased expression of miR-15a/16-1 caused by TSA treatment, which reduced the expression of an important survival protein named Bcl-2 [ 57 ]. Furthermore, TSA showed potent cytotoxic activity against both human small- and non–small-cell lung cancer cells (SCLC and NSCLC). In SCLC, TSA caused morphological differentiation and apoptosis, which was associated with an upregulation of acetylated histone 4, p21 and p27, cleavage of PARP protein and a decline of antiapoptotic protein BCL-2 levels in the DMS53 cell line [ 103 ]. While, in NSCLC, TSA induced growth inhibition via apoptosis, with the concomitant enhancement of histone H4 acetylation and p21 expression in four cell lines including Calu-1, NCI-H520, NCI-H23, and NCI-H441 [ 93 ]. Thus, TSA showed a potent activity against lung adenocarcinoma in vitro , which requires further studies to reveal this compound’s efficiency and safety in vivo. TSA possesses a significant inhibitory effect against colorectal, gastric, and esophageal cancer cells by inducing apoptosis and cell cycle arrest. Published research indicated that TSA induces cell growth inhibition and apoptosis in colon cancer via epigenetic modification. This effect was linked to the upregulation of p21, p27, and p57 expression with the concomitant suppression of DNMT1 and HDAC1 in colon cancer SW480 cell line [ 48 ]. In addition, TSA inhibited colon cancer cells by altering claudin-1, a protein involved in the growth of colon cancer at high levels. Furthermore, TSA decreased the stability and suppressed the expression of claudin-1 mRNA by reducing the binding of HuR and increasing the binding of TTP to the 3′-UTR of claudin-1 in human colon cancer cell lines SW480 and SW620 [ 109 ]. It also inhibited the cell invasion and migration of colorectal cancer cells by decreasing vimentin and promoting E-cadherin expression, resulting in reversing EMT in the SW480 cell line. The regulation of E-cadherin and vimentin expression by TSA was suggested to be mediated by the decline of transcription factor Slug [ 124 ]. In gastric cancer cells, TSA induced apoptosis and cell cycle arrest, which was associated with a significant decrease in glycoprotein non-metastatic melanoma protein B (GPNMB) expression. GPNMB is highly expressed in gastric cancer tissue compared with normal tissues suggesting that the TSA effect against gastric cancer could be mediated by the downregulation of GPNMB [ 104 ]. According to Wang et al. [ 123 ], the apoptosis induced by TSA was linked to an increase in the p21, p53, and Bax expression and a decrease in Bcl-2, CDK2, and CyclinD1 expression in the AGS gastric cancer cell line. TSA induced DNA damage in human esophageal cancer cell lines EC109 and KYSE150, with the upregulation of Rad9 gene expression at mRNA and protein levels only in EC109 cells. The knockdown of Rad9 by siRNA increased the DNA damaging effect of TSA [ 99 ]. It also significantly inhibited the invasion and metastasis of esophageal squamous cell carcinoma. The anti-invasive effect induced by TSA was mediated by the downregulation of HDAC2, which led to a decline in MMP-2 and MMP-9 expression [ 123 ]. These preliminary findings showed that TSA could be involved in treating colorectal, gastric, and esophageal cancers. Recently, two separable ERK1/2-dependent signaling pathways including an ERK1/2–Slug branch and an ERK1/2-PAI- 1 branches were involved in TSA-induced ESCC cell migration. Both TSA-induced ESCC cell migration branches favored the EMT process, while BRD4 was responsible for two separable ERK1/2-dependent signaling pathways [ 147 ]. Liu et al. [ 82 ] evaluated the altered expression of genes associated with the cell cycle after TSA treatment. Their results revealed a significant reduction of mini-chromosome maintenance protein-2 (MCM-2) in colon cancer cells that was attributed to the increase in phosphorylated JNK, by TSA treatment resulting in cell growth inhibition and apoptosis [ 82 ]. Similarly, Dai et al. (2019) provided further evidence on the cytotoxic mechanism of action of TSA. TSA and the IRE1α/XBP1 pathway in WT HCT116 cells induced ER stress and the ER stress was attenuated by the mutation or silencing of TP53. In addition, these researchers showed that the cell viability was increased and the apoptosis rate was reduced in HCT116 TP53(-/-) cells compared with WT HCT116 cells after TSA treatment. Taken all together, these results revealed that TSA-induced ER stress may occur via a p53-dependent mechanism in colon cancer cells, and induction of apoptosis via p53 signaling pathway activation was supported by other studies [ 148 ]. In a recent study, An et al. [ 15 ] investigated the antitumor activity and the mechanism of modulating gastric cancer cell growth by TSA. They showed an antiproliferative effect of TSA against MKN-45 and SGC-7901 cells, which significantly suppressed the number and size of colonies. Moreover, flow cytometry methods revealed that TSA induces G1 phase cell cycle arrest and apoptosis and affected the expression of related factors in mitochondrial apoptotic signaling and cell cycle-related regulatory pathways. In addition, TSA increased the acetylation of histone H3K27 and downregulated the expression of PI3K and p-AKT. In a similar fashion, Han and coworkers [ 149 ] reported that TSA treatment induces mesenchymal-like morphological modifications BGC-823 human gastric cancer and increases the expression rate of the mesenchymal markers vimentin and twist. It also suppressed cancer cell colony formation in both cell lines and led to the deregulation of the critical signaling molecule involved in EMT named β -catenin. TSA can inhibit hepatocellular carcinoma through mitochondrial and cytoplasmic apoptotic pathways in HCCLM3, MHCC97H, and MHCC97L cell lines, with no effect on primary hepatocytes. It altered the expression of many genes involved in cell growth, differentiation, and apoptosis such as Bax, Bak, Bim, p53, and p73 that were up-regulated by TSA. At the same time, Bcl-2, Bcl-xL, Mcl-1 were downregulated with TSA treatment [ 47 , 100 ]. In addition, TSA inhibited the cell growth and induced apoptosis in hepatocellular carcinoma via the re-activation of ERα gene expression in the Hepa1-6 cell line [ 47 ]. In human hepatoma cell lines including HuH7, Hep3B, HepG2, and PLC/PRF/5 cells, TSA inhibited cell growth in a concentration-dependent and time-dependent manner against all studied cell lines. Moreover, the results revealed that TSA suppresses cell growth, induces apoptosis, and inhibits specific genes expression in hepatoma cell lines [ 60 ]. Research findings showed that TSA can act against human pancreatic cancer cell lines by enhancing the expression of pro-apoptotic genes such as the BIM gene, and suppressing the expression of anti-apoptotic genes like Bcl-XL and Bcl-W [ 91 ]. In this respect, Zhang et al. [ 134 ] indicated that the apoptotic effect induced by TSA was linked to the alteration of microRNAs expression in BxPC-3 human pancreatic cancer cells inhibiting their proliferation [ 134 ]. To explore the potential effects of TSA against pancreatic cancer (PC) cells, Emonds et al. [ 30 ] demonstrated that the cytotoxic effect of TSA in PC cells is associated with the increase of acetyl-H3, p21Waf1, phospho-p38 and Bax levels, and the decrease of phospho- ERK 1/2 and phospho-AKT. Similarly, Chen et al. [ 58 ]. showed that TSA can induce apoptosis of pancreatic cancer cells. TSA treatment significantly increased the expression levels of Bax and caspase-3 resulting in reduced survivin and anti-apoptotic Bcl-2 [ 58 ]. TSA exhibited considerable anti-leukemic effects by regulating the cell cycle and inducing apoptosis in numerous human leukemic cell lines, with low toxicity against normal peripheral blood mononuclear cells (NPBMNC) [ 53 , 107 , 115 ]. It caused the growth inhibition and morphological changes in a human leukemic cell by inhibiting cyclins and the proliferating cell nuclear antigen (PCNA), positive regulators of cell cycle progression, and by the upregulation of Cdk inhibitors such as p16, p21 and p27 [ 126 ]. It additionally showed potent activity against chronic lymphocytic leukemia (CLL) cells through caspase-dependent inhibition of Wnt [ 102 ]. Wnt is highly expressed in CLL and is involved in developing several types of cancer. TSA treatment led to the upregulation of caspases-3 and 7 activity and DKK1 mRNA expression known as a negative regulator for the Wnt. TSA inhibited CLL cells via the modulation of histone acetylation by inhibiting H4 histone deacetylation [ 102 ]. In TK6 human B lymphoblastoid, TSA induced G1 cell cycle arrest and apoptosis in a caspase 3–independent apoptotic pathway. Furthermore, the cytotoxicity effect of TSA in TK6 cells might be linked to the ability of this compound to cause DNA and chromosome damage through chromosome breakage and by increasing the levels of aneuploidy [ 98 ]. In addition to its potent antitumor effects, numerous studies showed that TSA exhibits an immune-regulatory effect. TSA suppressed the expression of the interleukin-2 gene in CD4+T-cells [ 92 ]. It also reduced the production of the pro-inflammatory cytokines (TNF-α and IL-6) and type I interferon (IFN-I) known for their role in autoimmune diseases [ 105 ]. TSA played an important role in the control of allergic airway inflammation mediated by Group 2 innate lymphoid cells (ILC2) activation, and downregulated the number of ILC2 expressing IL-5 and IL-13 cytokines and consequently attenuated lung eosinophilia and mucus hypersecretion in a mouse model [ 119 ]. TSA also affected cell cycle progression in Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell lines LCLs (SNU-20 and SNU-1103). EBV is a ubiquitous human herpes virus recognized as being instrumental in causing human malignancies of lymphoid [ 150 ]. In this regard, the induction of EBV lytic antigens is one of the strategies used to treat EBV-associated malignancies. At this level, TSA induced EBV lytic replication by upregulating EBV lytic genes expression (BZLF1, BMRF1, gp110, BRLF1, BALF5, BBLF2/3 and gp350) in lymphoblastoid cell lines [ 107 ]. These important results show that TSA exhibits a cytotoxic effect and immunomodulatory potential suggesting this compound’s use in the therapy of leukemia and the treatment of autoimmune and inflammatory diseases. The anti-proliferative effects of TSA were also reported in murine pro-B lymphoma cell line FL5.12. TSA exerted a potential inhibition of the proliferation of FL5.12 cells in a time and dose-dependent manner. TSA treatment led to DNA fragmentation and the activation of caspase-3 and PARP, resulting in the release of apoptotic protein Bim [ 80 ]. Anti-Molt-4 cell activity of TSA was also reported in a time- and dose-dependent manner by Hong et al. [ 31 ]. These authors concluded that the TSA growth-inhibition effect could be attributed to its apoptosis-inducing effect on Molt-4 cells [ 31 ]. Findings showed that TSA inhibits tumor growth in MG-63 osteosarcoma cells in vitro and in vivo . This antitumor effect upon TSA treatment is partially mediated by the suppression of HIF-2α protein expression. Thus, TSA could be used to treat excessive bone resorption by inducing osteoclast apoptosis via the upregulation of p21 WAF1 . Osteoclasts can cause many pathologic conditions such as osteoporosis and tumor-induced bone destruction [ 131 ]. Deng et al. [ 26 ] suggested that TSA significantly inhibits cell growth and promotes apoptosis in a dose-dependent manner through p53 signaling pathway activation in MG63 cells [ 26 ]. Moreover, TSA was tested in wild-type p53 (HT116 cells) and mutant p53 (HT29 cells) colorectal cancer cell lines. Results showed that it induces apoptosis, enhances the expression of Bax, lowers the levels of Bcl-xl and Bcl-2, and induces cell cycle arrest in the G2/M phase [ 89 ]. In addition, TSA induced apoptosis and cell cycle arrest in the G2/M phase in colorectal cancer cells via p53-dependent and -independent pathways. TSA also inhibits proliferation, induces apoptosis, inhibits the invasiveness of osteosarcoma cells in vitro, and arrests the cell cycle in the G1/G2 phase in Osteosarcoma cells [ 59 ]. It also had a role in inducing autophagy in human osteosarcoma (U2OS) cells through the rapamycin (mTOR) signaling pathway and enhances forkhead box O1 (FOXO1) transcriptional activity [ 34 ]. Using immunofluorescence, immunoprecipitation, Western blots, and qPCR, Geng et al. [ 50 ] studied the cell proliferation, cell cycle, survival mechanisms, the localization and post-transcriptional modification of GLI1 protein, the target gene P21 of RPMI8226, and MM.1S cells treated with TSA. TSA exerted a time and dose-dependent MM cell growth repression, and induced cell apoptosis via the abrogation of hedgehog signaling. TSA treatment exhibited versatile effects on the hedgehog transcriptional factor GLI1. The proteasome-dependent degradation of GLI1 was promoted by TSA-mediated acetylation, and TSA-induced p21 upregulation damages the transcription of GLI1 [ 50 ]. In rhabdomyosarcoma (RMS), a common type of musculoskeletal sarcomas, TSA inhibited cell proliferation and reversed RMS malignancies behavior by reactivating its differentiation to the original skeletal muscle type. The activity of TSA in RMS cells was suggested to be mediated by the modification of small miRNAs expression, notably by the upregulating of miR-27b, which is involved in the process of myogenesis [ 117 ]. TSA induced apoptosis in mastocytoma cells in histone acetylation- and mitochondria-dependent pathways. It increased the acetylated histones, H2A, H2B, H3 and H4, activated caspase-3, induced cleavage of poly (ADP-ribose) polymerase (PARP), and decreased Bcl-2, Bcl-xL levels in mastocytoma cell line p815 resulting in a reduction of their mitochondrial membrane potential. TSA treatment showed a reduction in number of viable cells and induced cell death by apoptosis in the MCT of canine [ 94 ]. Several studies confirmed the potent antitumor activity of TSA against breast cancer in vitro and in vivo in a dose-dependent manner through different pathways. TSA-induced apoptosis and cell cycle arrest at the G2/M in both estrogen receptor (ER)-positive and ER-negative breast cancer cells in vitro and in vivo , with no toxic effect on the normal cells such as MCF-10A [ 116 , 118 , 120 , 121 ]. ERα played an essential role in the proliferation of ER-positive breast cancer. Interestingly, TSA was revealed as a potent ERα inhibitor. Therefore, breast cancer cells expressing ER were found to be more sensitive to TSA than the ER-negative cell lines [ 121 ]. In ER-positive cell lines such as MCF-7 and T47-D cells, TSA induced a long-term degradation of cyclin A, a decrease of Bcl-2 and myc-c, and a proteasome-dependent loss of ERα and cyclin D1, which led to the re-expression of p21 WAF1/CIP1 (cell cycle inhibitor) and RhoB GTPase (tumor suppressor) [ 120 , 139 ]. These findings indicate that TSA could be used in the endocrine therapy of breast cancer. In the ER-negative cells like MDA-MB-231 and SKBr-3 cell lines, TSA enhanced the expression of ERα mRNA and p21 WAF1/CIP1 at the protein level, and declined cyclin A, with the ability to cause cleavage of polyADP-ribose polymerase (PARP) [ 120 ]. Noh et al. [ 97 ] showed that TSA lowered the ERα protein expression under both normoxia and hypoxia via a proteasome-mediated pathway and enhanced the downregulation of ESR1 transcription under hypoxia conditions [ 97 ]. In the H-ras-transformed human breast epithelial (MCF10A-ras) cells, TSA induced morphological changes and cell cycle arrest by increasing the expression of p53 and p21 WAF1/Cip1 and activating ERK1/2. The cytotoxic effect of TSA against MCF10A-ras cells was partly linked in par to its ability to decrease phosphorylated Rb expression [ 151 ]. The inhibition of breast cancer cells with TSA treatment depends on the mitochondrial-mediated ROS by suppressing the activities of mitochondrial complexes I and III. Unfortunately, this pathway could be blocked by antioxidants such as GSH, NAC, and vitamin C [ 116 ]. On the other hand, TSA could also initiate cell cycle arrest and apoptosis via the 15-Lox-1/13(S)-HODE pathway by the induction of 15-Lox-1 activity associated with the elevation of 13(S)-HODE (15-Lox-1 metabolite) [ 118 ]. Furthermore, aberrations of microRNAs expression were confirmed to have a noticeable effect on cancer development [ 152 ]. In this respect, TSA modified the expression of microRNAs in the apoptosis-resistant MCF-7TN-R cell line. Additionally, TSA significantly upregulated the expression of many microRNAs considered tumor suppressors or involved in anti-migration, cell cycle arrest, anti-metastatic, and anti-EMT effects. TSA decreased the expression of microRNAs characterized as oncomiRs, which are involved in tumorigenesis [ 29 ]. Moreover, TSA was found to suppress the invasion and migration of MCF-7 cells by reversing EMT via knockdown of zinc finger protein SNAI2 (SLUG), which led to the upregulation of E-cadherin and downregulation of vimentin expression [ 153 ]. TSA showed great antitumor activity in vivo in breast cancer xenografts and carcinogen-induced rat mammary cancer models [ 120 , 121 ]. All these results provided a rationale for the important role of TSA in treating breast cancer due to its ability to induce cell growth inhibition and metastasis in different breast cancer types in vitro and in vivo . In 2006, Alao et al. [ 24 ] investigated the role of GSK3β in mediating the cytotoxic activities in MCF-7 breast cancer cells treated with TSA. These researchers showed that TSA induces Akt dephosphorylation in a PP1-dependent manner resulting in the activation of GSK3β in cells tested. These findings identified GSK3β as an interesting mediator of TSA-induced cytotoxicity in MCF-7 breast cancer cells [ 24 ]. In other research work, TSA was tested in T-lymphoblastic leukemia cell line Molt-4 cells. A time- and dose-dependent manner of proliferation inhibition of Molt-4 cells was observed. The application of TSA at different doses (from 50 to 400 μg/L for 24 h) decreased the percentage of G0/G1 cells and arrested cells in the G2/M phase by reducing the expression of HDAC8 in Molt-4 cells [ 66 ]. To explain the effects of TSA on epithelial-mesenchymal transition (EMT) in human cancer cells, Han et al. [ 149 ] reported that TSA treatment induces mesenchymal-like morphological modifications in MCF-7 breast cancer cells and BGC-823 human gastric cancer, increases the expression rate of the mesenchymal markers vimentin and twist, and suppresses cancer cell colony formation in both cell lines which led to the dysregulation of the critical signaling molecule involved in EMT named of β -catenin. In another study, Gao and coworkers [ 35 ] investigated the antitumor effect of TSA in H-ras-transformed human breast epithelial cells (MCF10A-ras cells) through a FOXO1-dependent pathway. TSA exhibited antitumoral activity in MCF10A. This antiproliferative effect was attributed to the induction of apoptosis in MCF10A-ras cells and the activation of FOXO1 via P21 upregulation, whereas the knockdown of FOXO1 reduced TSA-induced cell death. TSA induced autophagy in MCF10A-ras cells by blocking the mTOR pathway [ 35 ]. Befor this, Alao et al. [ 51 ] investigated the mechanisms underlying the antiproliferative effect of TSA. It caused G1-S-phase ER alpha-positive MCF-7 cell cycle arrest because TSA repressed ER alpha and cyclin D1 transcription and induced ubiquitin-dependent proteasomal degradation of cyclin D1. However, in the ER alpha-negative MDA-MB-231 cell line, cyclin D1 degradation was enhanced but its transcription was unaltered by TSA, resulting in cell cycle arrest in the G2-M phase [ 51 ]. Skp2/p45, a regulatory component of the Skp1/Cullin/F-box complex is involved in cyclin D1 degradation, which causes the silencing of SKP2 gene expression by RNA interference stabilizing cyclin D1 and abrogated the cyclin D1 downregulation response to TSA [ 51 ]. Similarly, TSA demonstrated anticancer potential by inducing apoptosis in MCF10A-ras cells via the activation of FOXO1, and the regulation of autophagy by blocking the mTOR signaling pathway [ 35 ]. TSA showed interesting results in the treatment of endometriosis. It significantly inhibited the proliferation in endometrial stromal cells, associated with the upregulation of PR-B and AR [ 127 ]. It additionally exhibited potent activity against cervical cancer cells [ 128 , 129 , 135 ]. TSA induced a delay in G2/M transition, the formation of defective mitotic spindles and misaligned chromosomes in a transcription-dependent manner by the downregulation of cell cycle regulators cyclin B1, Plk1 and survivin, and upregulation of p53, p21 Waf1 , and p27 Kipl in HeLa cell line [ 96 , 129 ]. Similarly, it inhibited the growth of HeLa cells via Bcl-2, oxidative stress- and caspase-dependent apoptosis, which was correlated with an increase in O 2 •− level, GSH depletion, the collapse of mitochondrial membrane potential (MMP), and a decrease of Bcl-2 protein and caspase-3 activation [ 130 , 132 ]. TSA also suppressed the expression of the ubiquitin-specific protease 22 (USP22), a gene overexpressed in most cancer cells and implicated in tumorigenesis [ 154 ]. The inhibition of cell proliferation by TSA was attributed to the ability of this compound to affect the physical and chemical nature of cytoskeletons, including microfilaments and microtubules, which play an important role in the maintenance of the cell morphology and material transportation in HeLa cells [ 137 ]. The cytotoxic effect of TSA was inhibited under the co-treatment of HeLa cells with the F-actin depolymerizers cytochalasin D (CytoD) and latrunculin B (LatB), indicating that TSA-induced apoptosis might require a dynamic rearrangement of F-actin [ 130 ]. It also suppressed rather than enhanced the radiosensitivity of HeLa cells at low doses [ 155 ]. On the other hand, Li et al. [ 79 ] studied the exact mechanism by which HDAC inhibitors induce p21 WAF1/CIP1 in HeLa cells. This team observed that TSA, an HDAC inhibitor, induced p21 WAF1/CIP1 expression in human cervical cancer (HeLa) cells, which is associated with the downregulation of c myc expression [ 79 ]. Interestingly, deeper insights were provided by Liu and colleagues [ 84 ] about the effects of TSA on cervical cancer development. The results showed that TSA suppressed the proliferation and induced apoptosis and autophagy in cervical cancer cells via the PRMT5/ STC1/TRPV6/JNK axis. TSA also reduced cervical tumor growth in mice xenograft models by the downregulation of osteopontin (OPN) gene expression. OPN is a secreted glycoprotein associated with tumor formation and metastasis. The gene expression of OPN was induced by PMA via the AP-1 transcription factor that forms a heterodimer of c-jun and c-fos at the OPN promoter. TSA suppressed the PMA-induced OPN gene expression by inhibiting c-Jun expression at the protein and RNA levels. Similarly, TSA inhibited the PMA-induced hyperacetylation of histones H3 and H4 associated with OPN promoter [ 108 ]. The results of the in vitro and in vivo studies revealed the high antitumor potential of TSA against cervical cell cancer and consequently the important role that TSA could play in treating this kind of cancer. Research findings revealed that TSA inhibits ovarian cancer cells by affecting their morphology and proliferation. This effect seemed to be linked to the ability of TSA to change the expression of p21, Rb, and Id1, which are involved in cell cycle control and differentiation in A2780 ovarian cancer cells [ 113 ]. Moreover, TSA induced apoptosis in ovarian carcinoma cells via a mitochondria-dependent pathway by increasing the protein expression of cytochrome c and P53 and the activity of caspase-3, -8 and -9 in OVCAR-3 cells [ 136 ]. The anticancer activity of TSA against ovarian carcinoma cells could be mediated by the upregulation of Krüppel-like factor 4 (klf4) which plays a tumor-suppressor role in the SKOV3 cell line upon TSA treatment [ 140 ], and the apoptotic effect induced by TSA was enhanced by the inhibition of Akt [ 136 ]. TSA exhibited antitumor activity against urinary bladder cancer cells. Bladder cancer is among the most expensive human cancer to treat with a high death rate. A preliminary study showed that the growth inhibition and apoptosis induced by TSA in urinary bladder cancer cells are correlated with a decrease of cyclin D1 and an increase in p21 expression, induction of PARP cleavage, mitochondrial membrane potential loss, inhibition of pAkt, and a decline of Sp1 and surviving [ 125 ]. However, the implication of TSA in the prevention and therapy of bladder cancer requires more investigations at different levels. A time and dose-dependent significant antiproliferative effect were reported in the human bladder cancer cell line, BIU-87, via the cell cycle arrest at the G1 phase and induction of apoptotic cell death was correlated with the increase of p21 WAF1 mRNA expression [ 79 ]. TSA increased the frequency of genetic recombination of spermatocyte meiosis and reduced testicular weight and sperm density in male mice [ 112 ]. It exhibited a noticeable antitumor activity against human prostate epithelial cells and induced cell growth inhibition and apoptosis in 267B1 cells in vitro via caspase-independent pathway and the activation of transcription factor nuclear factor kappa B (NF−κB) [ 151 ]. In the DU145 prostate cancer cell line, TSA treatment induced morphological changes and cell cycle arrest, inhibiting survivin expression and enhancing P21 protein expression [ 133 ]. However, conflicting results concerning the effect of TSA on cell migration were reported for prostate cancer. Wang et al. [ 124 ] revealed that TSA inhibits the cell migration of prostate cancer cells by reducing the expression of the transcription factor, Slug, which suppresses vimentin and enhances E-cadherin reversing EMT in the PC3 cell line [ 124 ]. However, Kong and coworkers [ 156 ] found that TSA induces EMT in prostate cancer cells and changes their cellular morphology. TSA-induced EMT was accompanied by the enhancement of vimentin, N-cadherin and fibronectin (mesenchymal markers), and the expression of ZEB1, ZEB2, and Slug (transcription factors), which correlated with an increase in tumor virulence. In-depth, experiments are required to determine the safe use of TSA in prostate cancer therapy focusing on the metastasis side. All related studies showed the potent anti-tumor effect of the TSA. It targeted several kinds of cancer and was involved in treating autoimmune and inflammatory diseases. It inhibited a wide range of cancer cells through different pathways without affecting normal cells. The main mechanism by which TSA protected non-cancer cells from apoptosis was via the activation of ERK1/2 (extracellular signal-regulated kinase) [ 135 ]. In addition, no toxicity was observed when high doses of up to 5 mg/kg of TSA were used, suggesting an added value to this compound [ 121 ]. However, in vivo experiments indicated that TSA is rapidly metabolized, complicating the clinical trials of this important compound and its use in cancer therapy. To overcome this problem, long-term treatment with a high dose of TSA, 500 mg/kg daily for 4 weeks by subcutaneous injection, showed great antitumor activity in the carcinogen-induced rat mammary cancer model [ 121 ]. In addition, efforts were made to develop formulations, that protect TSA molecules from inactivation. In this respect, TSA-loaded liposomes (TSA-lipo) formulations significantly protected TSA from inactivation. Subsequently, they resulted in potent growth inhibition of both ER-positive and–negative BC cells in vivo at low TSA concentration (1.5 mg/kg/week) by intravenous injection. The anticancer effect of TSA-lipo was characterized by the inhibition of Ki-67 labeling, inhibition of tumor vasculature, and an increase of p21 WAF1/CIP1 in MCF-7 and MDA cells xenografts [ 120 ]. On the other hand, several problems related to the possibility of TSA inducing EMT and enhancing cell cancer migration still need to be carefully addressed and clarified. Therefore, the safe use of TSA in cancer therapy requires further investigations to determine the specific conditions TSA could induce rather than reverse EMT in cancer and consequently increase cell cancer invasion and migration. Also, combinatorial treatment of TSA with a potent EMT-inhibitor could help avoid EMT induction and metastasis upon TSA treatment. Further studies are needed to show the antitumor activity of TSA in vivo in numerous cancer types. Considering the role of various anticancer drugs in chemotherapy and the emergence of chemoresistance, the effect of TSA on the chemosensitivity of several anticancer drugs in cancer cells was investigated by numerous research groups. Findings emphasized that TSA is a potent chemo-sensitizer in human cancer cells to improve chemosensitivity towards many drugs including cisplatin, valproic acid, etoposide, tamoxifen, gemcitabine, 5-fluorouracil, oxaliplatin, irinotecan and gefitinib, sunitinib, and TRAIL. It also enhances the radiosensitivity of cancer cells. Moreover, many molecules, such as genistein, quercetin, and glycyrrhetinic acid potentiated TSA’s anticancer activity against different cancer cell lines. Along this line, TSA reestablished cisplatin sensitivity in many cisplatin-resistant cancer cells and augmented cisplatin activity by eliciting cisplatin-induced apoptosis via various mechanisms. In the head and neck squamous cell carcinoma cell line (UT-SCC-77), cisplatin-induced apoptosis was enhanced by TSA pretreatment [ 36 ]. TSA decreased lysosomal pH, which augmented cathepsin activity resulting in reduced LAMP-2 level, and the potential LMP promotion. Cells lacking LAMP-2 became more sensitive to cisplatin-induced apoptosis. Earlier work indicated that a lower lysosomal pH increases the efficiency of cisplatin-induced apoptosis. It reduces lysosomal pH and elicits lysosomal proteases and sensitized cells to cisplatin [ 36 ]. Numerous studies showed that the resistance of ovarian cancer cells to the proapoptotic effects of chemotherapy is partly due to the deficiency in Apaf-1 activity. Tan et al. [ 157 ], while evaluating Apaf-1 function showed that TSA restores Apaf-1 function in chemoresistant ovarian cancer cells, sensitizing them to cisplatin-induced apoptosis via the activation/cleavage of procaspase-9. Cisplatin stimulated mitochondrial release of cytochrome c , which was then complexed with Apaf-1. The latter bound and activated caspases-3 and -9, leading to apoptosis [ 157 ]. Recently, Lambert et al. [ 39 ] reported that TSA reduces cell viability in cisplatin-sensitive (A2780WT) and reestablishes cisplatin sensitivity in human ovarian cancer cells cisplatin-resistant (A2780RES) by eliciting cisplatin-induced apoptosis (boosted caspase-9 activity), autophagy (increased LC3-II expression), and cell cycle arrest (increased p21 expression). TSA additionally reduced taurine transporter (TauT) expression/activity in A2780RES cells to values similar to A2780WT cells suggesting a synergistic activation of apoptosis /autophagy and reduced TauT activity rather than facilitating cisplatin uptake or increasing cisplatin-induced DNA damage. TSA synergistically enhanced the antitumor effect of cisplatin and re-sensitized cisplatin-resistant bladder cancer cells leading to 90% death of T24R2 cells [ 41 ]. It was suggested that the potent synergistic effect could involve cell cycle arrest by potentiating cisplatin-induced S and G2/M phase cell cycle arrest and the induction of caspase-mediated apoptosis and/or the upregulation of the expression of proapoptotic proteins, Bad and Bax. In human lung adenocarcinoma cell line A549 and CDDP-resistant derivative (A549/CDDP), Wu and colleagues [ 158 ] showed that a low concentration of TSA sensitized cisplatin-resistant apoptosis. TSA upregulated pro-apoptotic proteins (death-associated protein kinase (DAPK)) mediating A549/CDDP cell death induced by cisplatin. TSA pretreatment induced elevation of the active form of DAPK in A549/CDDP, which elicited the chemosensitivity of cells to cisplatin. Similarly, co-treatment of human urothelial carcinoma (UC) cell lines (NTUB1 and T24) with TSA and three chemotherapeutic agents (cisplatin, gemcitabine, and doxorubicin) induced synergistic cytotoxicity and significantly potentiated apoptosis. The combination acted by suppressing Raf/MEK/ERK pathway as it is involved in many aspects of tumorigenesis, including cell growth, proliferation, survival, apoptosis, and chemoresistance in UC [ 159 ]. The activated Raf/MEK/ERK pathway was observed in human bladder UC specimens from patients with chemoresistant status. The co-treatment with TSA increased cleaved caspases-3,-7, and PARP compared with those induced by chemotherapeutic agents alone, and also suppressed the chemotherapy-induced activation of phospho-Bcl2, an anti-apoptosis regulator. The same conclusions were confirmed, in vivo, in a xenograft nude mouse model. Several studies reported that hepatitis B virus X protein (HBx) exerts anti-apoptotic effects leading to a potent chemoresistance effect in hepatocellular carcinoma (HCC) cells. In this respect, Zhang et al. [ 135 ] showed that the pretreatment with TSA and etoposide could significantly overcome the increased resistance of HBx-expressing HCC cells to chemotherapy. This combination significantly sensitized HBx-expressing liver cancer cells to etoposide treatment via the induction of apoptosis by inhibiting ERK phosphorylation, reactivating caspases and PARP, and inducing translocation of p53 and Bid to the cytoplasm [ 135 ]. In another study, the co-treatment of drug-resistant non-small cell lung carcinomas (NSCLC) (H157, H23 and H1299) with etoposide and TSA induced apoptotic through caspase-dependent pathway accompanied by a significant decrease in Bcl-xL expression allowing Bax activation. A subsequent initiation of the apoptosis, inducing factor (AIF)-dependent death pathway in H157 cells was also observed [ 160 ]. Moreover, in human leukemia cell lines (HL60 and U937 cells), the use of TSA and valproic acid (VPA) potentiated etoposide-induced cytotoxicity and apoptosis, which was associated with the activation of caspases and the loss of mitochondrial membrane potential [ 161 ]. TNF-related apoptosis-inducing ligand (TRAIL) is a potent anti-cancer agent due to its high selectivity in eradicating cancer cells while sparing normal cells. However, different cancer cells showed TRAIL resistance. In this context, numerous studies reported that TSA enhances TRAIL efficacy and re-sensitizes various cancer cells resistant even at high doses of TRAIL. Researchers [ 162 ] showed that low doses of TSA sensitized MM1S myeloma cells were resistant to TRAIL-induced apoptosis and enhanced TRAIL cytotoxicity through the caspase-independent pathway. It induced apoptosis involving the downregulation of the antiapoptotic Bcl-2 proteins, Bcl-2 and Bcl-X L , without altering FLIPS expression. The expression of Bcl-2 members (Bim and Bid) was also upregulated while the expression of PUMA (a and b), Bax, and Noxa, was down-regulated. TSA also induced the transcription of TRAIL death receptor DR5. In another study, Kong et al. [ 156 ] showed that zebularine and TSA with TRAIL (TZT) treatment sensitizes human breast adenocarcinoma cells (MDA-MB-231 and MCF10A) and augments apoptosis as compared with TRAIL alone. Apoptotic features, including morphological changes, apoptotic activity, and the expression of cleaved poly (ADP) ribose polymerase (PARP) protein were more prominent in MDAMB-231 as compared to MCF10A. No changes in cell cycle were recorded in MDA-MB-231 cells under TRAIL and TZT treatments suggesting other mechanisms [ 156 ]. Similarly, researchers showed that the co-treatment of human TRAIL-resistant ovarian cancer cells (SKOV3 and Hey8), with TSA and TRAIL inhibits cell proliferation and sensitizes them to TRAIL-induced apoptosis through caspase-dependent mitochondrial pathways [ 101 ]. Moreover, treating SKOV3 cells with TSA and TRAIL significantly accelerated caspase-8 and truncated Bid resulting in the cytosolic accumulation of cytochrome c and the activation of caspases-3 and -9. On the other hand, the cleavage of PARP, an endogenous substrate of caspase-3, and the upregulation of Bax led to a significant loss of Bcl-2 and Bcl-xL. The sensitization was associated with the downregulation of c-FLIP L via the inhibition of the EGFR pathway, involving caspase-dependent mitochondrial apoptosis as TRAIL alone did not alter the protein level of c-FLIP. In gastric cancer cell lines (AGS, NCI-N87, SNU-1 and SNU-16), TSA potentiated TRAIL-induced apoptosis in caspase-dependent manner via the inhibition of the ERK/FOXM1 pathway [ 80 ]. The combination rendered gastric cancer cells more vulnerable to TRAIL-mediated cytotoxicity and suppressed cell viability in TRAIL-resistant cell AGS and SGC-7901. In the absence of TSA, slight activation of caspases-3, -7, -8, -9, and PARP was observed, whereas the cotreatment greatly potentiated these effects in both SGC-7901 cells. TSA also contributed to the upregulation of DR5 and downregulation of antiapoptotic proteins (XIAP, Mcl-1, Bcl-2 and Survivin) that could be regulated by oncogenic transcription factor Forkhead boxM1 (FOXM1). TSA treatment inhibited FOXM1 expression at both the transcription and protein levels. The expression level of FOXM1 showed a negative correlation with TRAIL sensitivity. FOXM1 downregulation could be ascribed to the inactivation of the ERK pathway, which sensitizes cells to TRAIL. Research findings [ 40 ] showed that TSA acts as a sensitizer in chemotherapy and enhances the response to chemotherapeutic agents (gemcitabine, 5-fluorouracil, oxaliplatin, irinotecan and gefitinib) in inhibiting ten pancreatic adenocarcinoma cell proliferation. Ten human pancreatic cancer cell lines, seven derived from primary cancer (MiaPaca2, PaCa3, PaCa44, Panc1, PT45P1, PSN1, and PC) and three from metastatic cancers (HPAF II, CFPAC1, and T3M4) were investigated. TSA was the best partner for all drugs except for 5-fluorouracil leading to potent inhibition of cell growth. The combination of TSA and irinotecan exhibited potent growth inhibition (80%) in most cell lines. In a similar fashion, Zhang et al. [ 163 ] showed that TSA increases the chemosensitivity of anticancer drugs in two human gastric cancer cell lines (OCUM-8 and MKN-74). The combination of TSA with five anticancer drugs, namely 5-fluorouracil (5-FU), paclitaxel (PTX), oxaliplatin (OXA), irinotecan (SN38), and gemcitabine (GEM) caused a synergistic anti-proliferative effect by combining TSA (30 ng/mL) with 5-fluorouracil, paclitaxel, and irinotecan [ 163 ]. These three anticancer drugs target cancer through different mechanisms and are used clinically. Furthermore, TSA upregulated the expression of p21, p53, DAPK-1, and the DAPK-2 gene in both OCUM-8 and MKN-74 cells which could be involved in the synergistic effect. The expression level of caspase-3 mRNA increased in OCUM-8 but not in MKN-74, suggesting a key role of caspase-3 in chemosensitivity induced by TSA. It was suggested that the bcl-2 family might not contribute to the enhanced chemosensitivity of TSA as no alteration of bcl-2 was observed. TSA sensitized estrogen receptor (ER) α-negative in formerly antihormone-unresponsive human breast cancer cells (MDA-MB-231, Hs578T and ZR75-1) to tamoxifen treatment possibly by upregulating ER β activity [ 164 ]. TSA enhanced the ER transcriptional activity as visualized by estrogen response element-regulated reporter and progesterone receptor expression. It seems that the high ER transcriptional activity is mediated by ER β rather than α as TSA induced the expression and nuclear translocation of ER β but not α. Sato et al. [ 165 ] showed that the combination of TSA-Sunitinib is effective against RCC cells 786-O, ACHN, and Caki-1 RCC cell lines, especially in 786-O, by enhancing apoptosis or growth inhibition through an increase of p21. VEGF protein expression was suppressed by the used combination. Flow cytometry revealed that the apoptotic cell population (sub-G1) was significantly higher in the TSA-Sunitinib combination group compared to the single SU treatment group. In ACHN cells, a cell cycle arrest at the S and G2/M phase was observed in the combined treatment group. Additionally, p21 was significantly increased in both 786-O and ACHN cells. In renal cell carcinoma (786-O, ACHN, and Caki-1 RCC cells), TSA reduced sunitinib resistance by triggering intracellular metabolome shifts [ 166 ]. Combined metabolome and transcriptome analysis suggested that TSA affects the energy productive metabolic pathways, such as those involving the TCA cycle and nucleotide metabolism. The combination of sunitinib and TSA increased cell death with PARP cleavage, an early marker of mitochondrial apoptosis. In contrast, the receptor tyrosine kinase signaling (the target of sunitinib) was not altered. The sunitinib resistant-RCC cell (786-O Res) when exposed to the sunitinib-TSA combination showed significant growth inhibition. Cells experiencing irreversible damage underwent apoptosis, causing an accumulation of cells in the sub-G1 population and the accumulation of cleaved PARP, introduced by caspase-3. In hepatoma cells (HepG2), Donia et al. [ 167 ] showed that TSA enhances responsiveness and induces apoptosis to Taxol. The sensitizing effect of acetylation modification on the responsiveness of hepatoma cells to anticancer therapy is ascribed to its modulatory role on epigenetics via the upregulation of HDAC1 and downregulation of Dnmt1 and 3α gene and drugs metabolizing genes. Many authors reported that TSA potentiated radio and chemosensitivity in various cancer cells through different mechanisms. In this respect, Karagiannis et al. [ 37 ] treated human erythroleukemic K562 cells with TSA and then exposed them to anthracycline, doxorubicin, or gamma radiation. TSA pre-treatment increased the radio- and chemo-sensitization, inhibiting cellular proliferation, reducing clonogenic survival, and inducing apoptosis. The pretreatment of K562 cells with TSA augmented the cytotoxic effect of doxorubicin [ 38 ]. Similarly, findings [ 37 ] confirmed that TSA enhances the sensitivity of K562 cells to radiation which caused the accumulation of γH2A.X. Caspases-3 and 7 are involved in radiation-induced apoptosis. The evaluation of caspases-3 and 7 levels indicated that TSA, at concentrations higher than 0.3 µM, potentiated radiation-induced apoptosis in a concentration-dependent manner. The sensitization effect could involve histone hyperacetylation and changes in phosphorylated H2A.X formation on euchromatin at a lower dose of TSA, whereas, at the higher dose it could involve cytotoxicity and G1 (>0.3 µM TSA) and cell cycle arrest at the G2/M phase (1 µM TSA). Moreover, Kim et al. [ 168 ] showed that TSA radio-sensitizes human head and neck cancer cell lines (HN-3 and HN-9 cells). TSA pretreatment (50 nM) significantly reduced the survival of HN-9 cells even at as low a radiation dose as 2 Gy (SF2) while in the HN-3 cell line, 200 nM TSA was necessary to show the effect [ 168 ]. In another study, Kim and coworkers showed that TSA enhances radiosensitivity by abrogating G 2 /M arrest in three cell lines (A549, HeLa, and Caski cells). The SF2 of TSA-treated cells was significantly lower than that of the mock-treated cells. The potent radiosensitivity observed is ascribed, at least in part, to the abrogation of radiation-induced G2/M arrest. Apoptosis was promoted when the cells were exposed to concentrations higher than 600 nM [ 169 ]. TSA also enhanced the radio-sensitivity of non-small cell lung cancer (NSCLC) (A549 and H1650 cells) to γ-irradiation [ 78 ]. In A549 cells, TSA caused both G1 and G2/M arrest and enhanced IR-induced accumulation of cells in the G2/M phase, with the upregulation of the expression of p21waf1/cip1 leading to cell cycle arrest. TSA co-treatment caused pronounced apoptosis through multiple pathways accompanied by p21waf1/cip1 cleavage. The enhanced apoptotic effect was mediated by the mitochondrial pathway, as indicated by the increased dissipation of mitochondrial transmembrane potential (MMP) and the release of cytochrome c from the mitochondria to the cytoplasm. Caspase-3 activation was also significantly increased, with more cleavage of PARP, associated with the repression of X-linked inhibitor of apoptosis protein (XIAP). TSA co-treatment also interfered with DNA damage repair processes and impaired DNA repair capacity after IR by the downregulation of Ku70, Ku80, and DNA-PKcs, as reflected by the enhanced and prolonged expression of γH2AX. Using cervical cancer HeLa cells, researchers showed that TSA synergistically enhances the DNA targeting capacity and apoptosis-inducing efficacy of silver nanoparticles (AgNPs) due to its effect on chromatin condensation and through the activation of the apoptosis effector caspase. Significant ROS generation was observed upon AgNP and TSA treatment corroborating that oxidative stress contributes to the cellular effects of both compounds. A high number of γH2AX foci was detected, suggesting the enhanced formation of double-strand DNA breaks with the combination treatment [ 170 ]. TSA sensitized the hepatocellular carcinoma cells (HCC) (HepG2 cells) to enhance NK cell-mediated killing by regulating immune-related genes. In this regard, Shin et al. [ 171 ] observed a significant alternation in the immune-associated genes in TSA-treated HepG2 cells, particularly concerning innate immunity-related genes and antigen recognition-related genes. These findings suggest that TSA induces NK cell-mediated anti-tumor effects in HCC. TSA indirectly increased the killing of HCC cells by increasing NK cell-directed killing and directly by increasing apoptosis. TSA regulated the transcription of numerous innate immunity and tumor antigen recognition-associated genes, such as ULBP1 and RAET1G, in HCC cells. In addition, TSA treatment of HepG2 cells rendered them more susceptible to NK cell-mediated killing while increasing the expression of NKGD2 ligands, including ULBP1/2/3 and MICA/B. TSA also induced the direct killing of HCC cells by stimulating apoptosis. Furthermore, TSA treatment increased nuclear fragmentation and apoptotic bodies in a dose-dependent manner and increased the cleaved (active) caspase-3 in HepG2 and Huh7 cells whereas, PARP, a critical DNA repair protein, was also cleaved by TSA treatment. In vivo , TSA also reduced tumor cell growth in an NK cell-dependent manner in an established HCC tumor xenograft model in BALB/c nude mice [ 171 ]. Roh et al. [ 172 ] showed that TSA treatment reduced cell viability of human osteosarcoma (HOS) cell lines by increasing apoptosis via altering the cell cycle progression. TSA treatment increased the percentage of G2/M-phase cells, while producing a concomitant fall in the rate of G0/G1 phase cells, causing an increase in apoptotic cell portions. The expression levels of Bcl-2 and XIAP have decreased in a time-dependent manner. As loss of MMP is known to be a common event in apoptosis induction, a quick reduction of MMP and the release of cytochrome c to cytosol were observed. Apoptosis involves the generation of DNA fragmentation, activation of procaspase-3, cleavage of PARP, and increased DNA hypoploidy. TSA induced apoptosis in HOS cells in histone acetylation- and mitochondria-dependent pathways. It synergistically sensitized HOS (CRL-1543 and MG-63) cells to the action of genistein [ 172 ]. Listed in Table 5 are the anticancer activity of TSA through sensitization. The sensitive effects the sensitizing effect of TSA on cancer cells towards drugs used in chemotherapy can be mediated by suppressing the resistance characteristics of tumor cells. In addition, the determination of the sensitizing molecular action of TSA could make it possible to set up the mechanisms of resistance to anticancer drugs. Numerous studies showed that some anticancer drugs enhanced the anticancer efficacy of TSA. Wu et al. [ 179 ] reported that the addition of genistein enhanced the inhibition of growth of A549 lung cancer cells and increased apoptosis induced by TSA via, at least in part, the up-regulation of the TNF receptor-1 (TNFR-1) death receptor signaling pathway. TSA, in combination with genistein increased TNFR-1 mRNA and protein expression, while TSA alone exhibited no changes. Moreover, the same combination increased the activation of caspases-3 and -10 and p53 protein expression. Genistein enhanced the effect of TSA by increasing the expression of TNFR-1, which activated the caspase cascade and resulted in apoptosis. The silencing of TNFR-1 expression negatively affected the genistein’s effect on TSA’s anticancer efficacy in human lung cancer A549 cells [ 179 ]. Similarly, TSA-induced apoptosis was synergistically enhanced by quercetin through the mitochondrial pathway in human lung cancer A549 cells [ 175 ]. The expression level of p53 was potentiated by the treatment with a combination of TSA and quercetin. In parallel, p53 silencing did not completely inhibit the augmenting effect of quercetin on TSA-induced apoptosis, suggesting the contribution of an additional p53-independent pathway. Quercetin synergistically enhanced the TSA-induced acetylation of histones H3 and H4 suggesting that quercetin enhances TSA-induced histone acetylation by p53-independent mechanisms; this may contribute to the enhancing effect of quercetin on apoptosis. The cotreatment with TSA-quercetin increased the expression of many mitochondria-associated pro-apoptosis genes, including Apaf-1, Bax, and caspase-9, and resulted in a marked release of cytochrome c into the cytosol, which demonstrated, at least in part, a mitochondrial pathway mechanism. Moreover, the cotreatment with TSA-quercetin was tested in a xenograft tumor model in nude mice leading to potent inhibition of tumor growth through the upregulation of p53 protein and a higher level of apoptosis [ 175 ]. In another study, Chan et al. [ 176 ] showed that quercetin dose-dependently enhanced the antitumor effect of TSA by upregulating the expression of p53. Quercetin prevented TSA-induced muscle wasting, at least in part, through the activation of Forkhead box O1 (FOXO1), the suppression of muscle wasting associated proteins atrophy gene-1 and muscle ring-finger protein-1 expression and increasing the myosin heavy chain level in the gastrocnemius muscles. Moreover, quercetin attenuated TSA-increased oxidative damage and the pro-inflammatory cytokines [ 176 ]. TSA-induced apoptosis was potentiated by 18β-glycyrrhetinic acid in human epithelial ovarian carcinoma cell lines (NIH-OVCAR-3 and SK-OV-3 cells) as reported by Lee et al. [ 177 ]. It was suggested that 18β-glycyrrhetinic acid might potentiate the apoptotic effect of TSA against ovarian carcinoma cell lines by increasing the activation of the caspase-8 dependent pathway and the activation of the mitochondria-mediated cell death pathway, leading to the activation of caspases. In fact, TSA induced nuclear damage, decreased Bid and Bcl-2 protein levels, increased Bax levels, caused cytochrome c release, activated caspases-3, -8, and -9, and increased tumor suppressor p53 levels. In addition to the promising anticancer activity of TSA confirmed by the multiple studies mentioned above, a synergistic effect of this molecule with other compounds was also proven. In 2002, Chen and collaborators were among the first researchers who sought the synergistic activity of TSA and other compounds to tackle colon cancer [ 180 ]. They conducted an in vitro study combining TSA with butyrate, a fatty acid produced by microbial fermentation of dietary fiber in the intestinal tract, to assess their anticancer effect against the SW620 human colon cancer cell line. This combination induced the expression of DNA damage-induced gene 45α (GADD45α) and GADD45β, belonging to a family of classical tumor suppressor genes [ 43 ]. These genes also promoted DNA repair and removed methylation markers [ 181 ]. The same results were obtained by combining TSA with cycloheximide, an antifungal that inhibits protein synthesis in eukaryotic cells. A year later, Rahman et al. [ 44 ] verified this synergistic effect of TSA with other compounds in mouse (ddY mice) and rats (male Sprague Dawley rats) bone marrow cultures and murine macrophage cell line RAW264 to elucidate their role in osteoclastogenesis [ 44 ]. TSA and sodium butyrate (NaB) showed several positive results including the inhibition of osteoclast formation, inhibition of osteoclast-specific mRNA expression in RAW264 cells, and reduction of trans-activation of NF-κB-dependent reporter genes. In another study, Min et al. (2004) evaluated the anti-proliferative activity of TSA with HC-toxin in two human breast cancer cell lines, MCF-7 and MDA-MB-468 [ 182 ]. These authors observed a strong activity against both cell lines and the induction of apoptosis and cell cycle arrest at the G 2 /M phase. Kang and al. [ 183 , 184 ] were among the first scientists who combined TSA with antioxidants to enhance the cytotoxic effect of combination therapy [ 183 , 184 ]. ROS are involved in various carcinogenesis stages [ 185 ], which explains the prolonged use of antioxidants in association with other anticancer drugs in the treatment of cancer. In the first study, and in addition to the cytotoxic activity observed in human leukemia cells (HL-60), the combined treatment decreased the generation of ROS. In contrast, in the second study it offered a protection against the Ni 2+ cytotoxicity in human hepatoma Hep3B cells. Scavenging ROS was the primary mechanism of action by which quercetin exerts its anticancer activity. This attracted the attention of two Chinese researchers to combine it with TSA against HL-60 cells [ 144 ]. This idea allowed the cytotoxic activity to increase in a dose- and time-dependent manner. This highlighted previous findings on the effect of combination on promoting histone acetylation and scavenging ROS. As mentioned in the previous sections, TSA alone inhibits the proliferation of cancer cells by inducing apoptosis and cell cycle arrest, as well as the transcriptional activation of NF-κB and p21 regulated by PKC. Interestingly, the addition of calphostin C, a PKC inhibitor, to TSA-based therapy against esophageal and lung cancer cells reduced TSA-mediated upregulation of NF-κB and p21. The combination of histone deacetylase inhibitor (trichostatin A) and protein kinase C inhibitor (calphostin C) induced apoptosis of lung and esophageal cancer cells [ 186 ]. Similarly, Jeon and his coworkers assessed the antitumor effect of TSA combined with gemcitabine, a chemotherapy drug against human bladder cancer cell lines (HTB5, HTB9, T24, J82 and UMUC14). These researchers showed that TSA synergistically potentiated the antitumor effect of gemcitabine, triggering cell cycle arrest and apoptosis and inducing repression of NF-κB signaling pathway activation [ 187 ]. In pancreatic cancer, the combination of TSA with gemcitabine suppressed the proliferation of human pancreatic adenocarcinoma cell lines in vitro and induced cell apoptosis by increasing the expression of the pro-apoptotic BIM gene accompanied by the downregulation of the 5’-nucleotidase UMPH type II gene [ 42 ]. Moreover, in vivo studies in xenografts of pancreatic adenocarcinoma cells in nude mice showed that this combination reduced tumor mass to 50% [ 42 ]. Furthermore, Hammer et al. [ 188 ]. investigated the in vitro and in vivo anticancer effect of the combinatory treatment of TSA with interferon β (IFN-β), a type of immunomodulating molecule known for its strong antitumor action, against human neuroblastoma cells (NB-1691 and NB-1643) and retroperitoneal human neuroblastoma xenografts. Results demonstrated that TSA acted synergistically with IFN-β, inducing a decrease in cell count compared to the controls in human neuroblastoma NB-1691 and NB-1643 cell lines. This effect was accompanied by the upregulation of p21Waf1 expression levels, especially in NB-1691 cells [ 188 ]. On the other hand, in vivo experiments showed that this combinatory based-therapy significantly restricted tumor growth in the murine model of neuroblastoma. In this respect, combining TSA with another HDAC inhibitor, valproic acid, inhibited the growth of neuroblastoma cells with IC 50 values ranging from 69.8 to 129.4 nM [ 189 ]. This combination induced the expression of CYP1A1, one of the main cytochromes P450 enzymes involved in the metabolism of carcinogens, which consequently potentiated its anticancer effect against UKF-NB-3 and UKF-NB-4 neuroblastoma cell lines [ 189 ]. In another study, using renal cell carcinoma (RCC) cells (SK-RC-39 and SK-RC-45 lines) and tumor xenograft model, Touma et al. [ 45 ] demonstrated that TSA and all- trans retinoic acid (ATRA) combinatory therapy might represent an effective strategy for the treatment of advanced RCC. These authors showed that TSA with ATRA suppressed the proliferation of RCC cell lines and tumor growth in a xenograft model through the reactivation of tumor suppressor genes such as the retinoic acid receptor β2 gene ( RARβ2 ) mRNA expression (8 h after treatment). They also observed that TSA and ATRA combination induced apoptosis and partial G0-G1 arrest in RCC SK-RC-39 cell lines [ 45 ]. Interestingly, focusing on developing a novel therapeutic strategy against ovarian cancer, particularly taxane-resistant ovarian cancer, Jin et al. [ 190 ] reported the possible mechanism of the synergistic anticancer effect of TSA with a proteasome inhibitor PS-341 in ovarian cancer A2780 cell line and its resistant variant, A2780T cells. The combination of TSA with PS-331 induced cell cycle arrest at the G2/M phase and apoptosis, and inhibited cell proliferation in A2780 and A2780T cells associated with the overexpression of cyclin B1. The Raf/MEK/ERK pathway has been the subject of intense investigations in the field of chemotherapy due to its multiple effects on cell growth, proliferation, prevention of cell-cycle arrest and apoptosis and the induction of drug resistance in different cell lines [ 191 ]. Thus, the Raf/MEK/ERK pathway represents an attractive target-based approach for cancer treatment. Addition of TSA to chemotherapeutic agents such as cisplatin, gemcitabine, or doxorubicin-induced synergistic cytotoxicity and concomitantly inhibited chemotherapeutic drug-induced activation of Raf-MEK-ERK signaling pathway in human urothelial carcinoma (UC) cells [ 159 ]. Activated Raf/MEK/ERK pathway is involved in the chemoresistant mechanism of UC [ 159 ]. These findings indicate that combining chemotherapeutic agents with TSA is a promising avenue to overcome the chemotherapeutic resistance of urothelial carcinoma cells via the inactivation of the c-Raf/ERK pathway. In addition, Yan et al. [ 192 ] investigated the role of the combinatory effect of TSA with curcumin, a polyphenol pigment obtained from Curcuma longa (turmeric), in the treatment of breast cancer. These authors showed that the combination of these two compounds inhibited cell growth and viability of MDA-MB435eB and SkBr3 cell lines. Moreover, TSA with curcumin induced cell apoptosis and G0/G1 cycle arrest in SkBr3 cells and G2M arrest in MDA-MB435eB cells. The molecular mechanisms underlying this synergistic effect were the activation of caspase-3 and poly(ADP-ribose) polymerase-1 cleavage, accompanied by a decrease of ERK and Akt phosphorylation and the up-regulation of p38 and JNK pathways [ 192 ]. Similarly, Piao et al. [ 193 ] studied the potential synergistic effect of TSA and BEZ235 (dactolisib), a dual pan-class PI3K and mTOR inhibitor, on the development of non-small-cell lung cancer (NSCLC). They reported that these two drugs cooperated to inhibit NSCLC proliferation, migration, and invasion, as well as the NSCLC epithelial-mesenchymal transition (EMT) in vitro , and to induce cell apoptosis. In addition, xenograft studies revealed that TSA combined with BEZ235 suppressed tumor growth and metastasis, and induced tumor necrosis in vivo [ 193 ]. In breast cancer, this combinatory therapy exerted significant synergistic growth inhibition of multiple cell lines by targeting caspase-dependent apoptosis and autophagic cell death pathway [ 194 ]. Shown in Table 6 are the synergistic anticancer activity of TSA. As can be seen, TSA can exhibit its anticancer action via different combinatory effects. Indeed, it potential the effects of used drugs in chemotherapy via its direct and/or indirect effects on cancer cell lines. This property should be explored and further investigations testing the combinatory effects of TSA with anticancer drugs in clinical trials. Recent investigations showed that cancer cells are characterized by epigenetic instability and memory disruption. During cell differentiation and development, memory cells are installed and maintained under epigenom programs. Epigenomic programs involve epigenetic modifications, which design changes in gene expression without any change in the physical structure of DNA. Several enzymes are involved in these epigenetic modifications including DNAT (DNA methyltransferase), which is responsible for DNA methylation, HDAC (histone deacetylase) and HAT (histone acetylase) which are responsible for histone modifications. Current molecular investigations indicated that the disruption of epigenetic marks can lead to cell transformation and tumorigenesis. Certain pharmacological investigations revealed the role of some molecules called epidrugs against cancer. These molecules target epigenetic perturbations and exhibit remarkable anticancer properties. The TSA direct effects on cancer cell lines, its chemosensitizing agent towards chemotherapy, and its synergistic effect with other chemotherapeutic drugs, suggest its potential as an important epidrug molecule against different human cancers. Ou et al. [ 227 ] surveyed the effect of TSA epigenetic regulation on histone modifications of human urinary bladder cancer T24 and human breast adenocarcinoma (MDA-MB-231) cells. Based on their investigation, TSA exhibited an increase in histone acetylation associated with a significant decrease in global methylation, induction of histone acetylation, demethylation, and expression of the methylated E-CADHERIN and RARβ2 genes, as well as some gene selectivity toward the studied cell lines [ 227 ]. In a similar fashion, scientists showed a high degree of histone deacetylation inhibition of TSA, associated with potent repression of MUC4 in high-expressing cells. Results highlighted the potential effects in preventing breast cancer with the use of 100 ng/mL of TSA combined with epigenetic modulator, genistein (GE), at a concentration of 25 μM. In this case, TSA inhibited HDAC, enhanced the re-expression of ERα in MDA-MB-231 cells, induced re-sensitization and reactivation of ERα-negative breast cancer cells to E2 and tamoxifen (TAM) antagonist, and promoted histone-remodeling changes in the ERα promoter [ 49 , 228 , 229 ]. The analysis of DNA methylation for a putative sphingosine-1-phosphate (S1P 1 ) promoter using TSA combined with 5-aza-2’-deoxycytidine (Aza-dC) in human melanoma cell line A2058 demonstrated the epigenetic regulation of S1P receptors in examined cells lines [ 230 ]. These findings indicated that TSA and Aza-dC mixture induces a switch of S1P from a motility inhibitor to a stimulator, enhancing the expression of S1P 1 and S1P 3 , associated with S1P-induced chemotaxis, and reduces the expression of S1P 2 related with motility suppression [ 230 ]. Similarly, Vincent et al. [ 49 ] established the restoration of MUC4 expression in a cell-specific manner after the treatment of pancreatic (PANC-1, CAPAN-1, and CAPAN-2) and gastric (KATO-III) epithelial cancer cell lines undergoing epigenetic regulation by the same combination of TSA and Aza-Dc [ 49 ]. According to these authors, the chromatin immunoprecipitation and RNA interference techniques confirmed that DNMT3A and DNMT3B were directly implicated in MUC4 silencing by binding to its 5′-UTR in a cell-specific manner [ 49 ]. Choi et al. [ 231 ] were interested in the TSA possible epigenetic modulation mechanism responsible for the inhibition of hTERT in the human colon cancer cell line (HCT116). For the first time in their survey, these scientists found that TSA exhibits a significant epigenetic role by inducing the demethylation of site-specific CpGs on the promoter of hTERT, which was due to DNMT1 downregulation [ 231 ]. TSA was also found to promote the CTCF binding on the hTERT promoter, resulting in the suppression of hTERT [ 231 ]. It was noted that the treatment with GE and TSA inhibited cell growth, downregulated the DNMT1 gene expression after 48 and 72 h of treatment, and DNMT3a gene expression only after 72 h, and promoted apoptosis in all tested groups of Human HCC HepG2 cells [ 47 ]. Importantly, TSA may play a role in preventing hepatocellular carcinoma by inhibiting apoptosis and reducing the expression of DNMT1. The relative expression of the DNMT1 gene ranged from 0.5 to 0.19 [ 232 ]. Recently, Sanaei et al. [ 106 ] showed dose and time-dependent antiproliferative effects (IC 50 ~1 μM) of TSA on hepa-6 cells, with a significant apoptotic action and a remarkable increase in the quantity of ERα gene expression [ 106 ]. To discover the main epigenetic pathways to limit the malignancy of ovarian cancer, Meng et al. [ 229 ] worked on the anti-ovarian cancer activity of TSA with decitabine. The treatment of SKOV3 cell line by TSA and decitabine significantly limited the activity of DNMTs, in particular, the expression of DNMT3A/3B. The combination therapy inhibited the invasion and tumorigenicity of ovarian cancer cells and suppressed migration capacity by the induction of E-cadherin and suppressing N-cadherin. The progression of the ovarian tumor was also repressed partially by the inhibition of MMP-9 and MMP-2 with this drug combination [ 229 ]. The micro-RNA (mRNA) was reported as another key in cancer epigenetic modification. Januchowski et al. [ 233 ] elucidated the role of TSA in Jurkat T leukemia cells clone E6-1 genetics character expression. By employing Western blot and quantitative real-time PCR methods, these researchers found that TSA can suppress the DNMT1 mRNA stability and protein expression in Jurkat T cells [ 233 ]. TSA increased the mRNA expression of the DKK1 gene in colon cancer cells [ 234 ]. Human malignant lymphoma CA46 cells were subjected to TSA alone or combined with epigallocatechin-3-gallate (EGCG) [ 179 , 235 ]. Results revealed that TSA alone inhibited CA46 cell proliferation, and when TSA (15 ng/mL) was combined with EGCG (6 μg/mL), the proliferation of CA46 cells from 24 to 96 h was decreased [ 235 ]. The co-treatment with TSA and EGCG downregulated p16 INK4A gene methylation, correlated with a rise in p16INK4A mRNA and protein expressions. This combination also reactivated p16 INK4A gene expression partially by lowering promoter methylation and reducing the CA46 cell overgrowth [ 235 ]. The above-mentioned studies proved the promising chemopreventive properties of TSA alone or in combination with other compounds and could be employed as a potential target in the treatment of hepatocellular carcinoma, breast, ovarian, and colon cancers.

The search for natural news with a pharmaceutical interest is supported today by several investigations. Indeed, natural molecules from different sources have been tested for their biological effects and pharmacological properties. The screening of natural substances with pharmacological properties involves in vitro screening, in vivo investigations, and clinical trials, including toxicological tests to validate the harmlessness of bioactive molecules [ 1 , 2 , 3 , 4 , 5 ]. Indeed, indeed, molecules of natural origin are favored over synthetic ones. This advantage is essentially due to the high toxicity of synthetic molecules. However, the toxicity assessment must also be done for natural molecules because some show specific toxic effects [ 6 , 7 , 8 ]. Trichostatin A (TSA) ( Figure 1 ) is a hydroxamic acid initially isolated from the secondary metabolites of Streptomyces hygroscopicus strains [ 9 ]. TSA is a known inhibitor of the canonical class I and class II histone deacetylases (HDACs) and one of the most promising agents with validated targets that prevent the progression of tumors [ 10 ]. The chemical structure of this compound plays an important role in its multiple biochemical and biological effects. TSA displays several pharmacological and physical properties, including antioxidant [ 11 , 12 , 13 , 14 ], antidiabetic [ 15 , 16 , 17 ], anti-inflammatory [ 18 , 19 , 20 , 21 , 22 ], and anticancer activities [ 23 , 24 , 25 , 26 , 27 , 28 , 29 ]. The antidiabetic effects of TSA are mainly related to its capacity to inhibit enzymes involved in the metabolism of glucides and lipids, as well as the signaling pathways involved in metabolism regulation [ 15 , 16 , 17 ]. On the other hand, the anti-inflammatory effects of this bioactive compound involve the inhibition of cytokines and other mediators of inflammatory processes [ 18 , 19 , 20 , 21 , 22 ]. Numerous reports focused on TSA’s in vitro and in vivo anti-tumor activity. These reports suggested four anticancer mechanisms of this substance. It can act directly on cell proliferation to activate the caspase pathway (inducing apoptosis) [ 30 , 31 , 32 ] and/or autophagy [ 33 , 34 , 35 ]. In addition, several reports indicated that TSA acts as a potent chemosensitizer on human tumors to improve chemosensitivity toward many drugs [ 36 , 37 , 38 , 39 , 40 , 41 ], and numerous studies highlighted the synergistic effect of TSA with chemotherapy [ 42 , 43 , 44 , 45 , 45 ]. Other reports emphasized the potent TSA effect in cancer epigenetic modifications [ 46 , 47 , 48 , 49 ]. Even though many studies usually reported the anticancer effect of TSA, to the best of our knowledge, no review was published to outline these reports critically and suggest future potential applications of this molecule as a promising agent in cancer therapy. Although some investigations have already focused on the biological effects and pharmacological properties of TSA, to the best of our knowledge, critical reviews on the development of TSA as anticancer drugs with other properties such as anti-inflammatory and antioxidant effects have not yet been reported. Accordingly, and owing to the wide range of preventive and therapeutic options of TSA against different types of cancer, this review highlights the chemopreventive and therapeutic ability of this natural compound and the mechanisms of its action with a list of related references. Moreover, the antioxidant, antidiabetic, and anti-inflammatory activities of TSA were also highlighted and discussed.

In this review, bibliometric research was done globally, without exclusion and/or inclusion criteria, from several databases, including Science Direct, PubMed, Google Scholar, Scopus, Wiley Online, and Web of Sciences. Different keywords, including trichostatin A, the antioxidant activity of trichostatin A, anticancer activity of trichostatin A, antidiabetic activity of Trichostatin A”, and anti-inflammatory activity of trichostatin A were used to obtain relevant literature. The data collected were classified according to different sections (sources and different biological and pharmacological properties). Then, the publications of each section were organized in tables and explored. These data were finally discussed and highlighted. The molecular structure of cirsimaritin was designed using the Chem-Draw program.

In conclusion, we summarized the biological and pharmacological properties of TSA, particularly anticancer properties. In addition, this review highlighted that TSA exhibits antioxidant, anti-inflammatory, antidiabetic, and anticancer effects with different mechanisms. It also exhibits remarkable in vitro and in vivo actions against different cancer cell lines such as breast, skin, and neuronal cancers. The anticancer properties of TSA involve pharmacodynamic actions including apoptosis, autophagy, anti-angiogenesis, and anti-telomerase. The exact molecular mechanisms with therapeutic correlations should be investigated to clarify the pharmacodynamic action. Among the remarkable anticancer mechanisms of TSA is its action on epigenetic pathways involved in cell memory. Therefore, further studies should be carried out to validate the use of this substance as an epidrug against some types of human cancers. TSA was used also in combination with other approved drugs, and it was shown that TSA improves the efficacy and therapeutic index of some used drugs. Moreover, TSA has also been shown to sensitize the treatment of other drugs used in chemotherapy. All these findings indicate that TSA is a very promising candidate as an anticancer drug; however, further pharmacokinetic investigations should be carried out to validate its absorption, bioavailability, metabolism, and elimination. Moreover, toxicological studies on animals and possibly in humans should also be tested to confirm its safety. This review could also give perspectives on the use of other natural molecules with chemical structure similarities. Furthermore, it has been demonstrated that there is a stochasticity of the biological effects linked to TSA, and this suggests that other natural molecules which may be stereochemically similar, or may have different functional groups, can also exhibit several pharmacological actions.